Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

被引：0
|
作者：
Takeru Shiroiwa
Takashi Fukuda
Kojiro Shimozuma
Mitsuko Mouri
Yasuhiro Hagiwara
Takuya Kawahara
Shozo Ohsumi
Yasuo Hozumi
Yoshiaki Sagara
Yasuo Ohashi
Hirofumi Mukai
机构：
[1] Department of Health and Welfare Services,Department of Biomedical Sciences, College of Life Sciences
[2] National Institute of Public Health,Department of Biostatistics, School of Public Health
[3] Ritsumeikan University,Biostatistics Division, Clinical Research Support Center
[4] Kanagawa Academy of Science and Technology (KAST),Department of Breast and Endocrine Surgery
[5] The University of Tokyo,Department of Integrated Science and Engineering
[6] The University of Tokyo Hospital,undefined
[7] Department of Breast Oncology,undefined
[8] National Hospital Organization Shikoku Cancer Center,undefined
[9] University of Tsukuba Hospital,undefined
[10] Department of Breast Surgery,undefined
[11] Ibaraki Prefectural Central Hospital,undefined
[12] Breast Surgery Department,undefined
[13] Social Medical Corporation Hakuaikai Sagara Hospital,undefined
[14] Chuo University,undefined
[15] Division of Breast and Medical Oncology,undefined
[16] National Cancer Center Hospital East,undefined
来源：
BMC Cancer | / 17卷
关键词：
Cost-effectiveness analysis; Quality-adjusted life years; Breast neoplasms; Randomized controlled trial; S-1; Taxoids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [42] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [43] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
  • [44] Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, I-year trial
    Tunis, SL
    Faries, DE
    Nyhuis, AW
    Kinon, BJ
    Ascher-Svanum, H
    Aquila, R
    VALUE IN HEALTH, 2006, 9 (02) : 77 - 89
  • [45] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
    Kim, Seung Tae
    Hong, Yong Sang
    Lim, Ho Yeong
    Lee, Jeeyun
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Chung, Ik-Joo
    Cho, Sang-Hee
    Lee, Kyung Hee
    Shin, Sang Joon
    Kang, Hye Jin
    Shin, Dong Bok
    Lee, Jae Won
    Jo, Sook Jung
    Park, Young Suk
    BMC CANCER, 2014, 14
  • [46] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
    Seung Tae Kim
    Yong Sang Hong
    Ho Yeong Lim
    Jeeyun Lee
    Tae Won Kim
    Kyu-Pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Ik-Joo Chung
    Sang-Hee Cho
    Kyung Hee Lee
    Sang Joon Shin
    Hye Jin Kang
    Dong Bok Shin
    Jae Won Lee
    Sook Jung Jo
    Young Suk Park
    BMC Cancer, 14
  • [47] Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
    Leung, John Hang
    Tai, Yun-sheng
    Wang, Shyh-Yau
    Fion, Hei-Tung Yip
    Tsung-chin, Ho
    Chan, Agnes Lf
    BREAST, 2022, 65 : 91 - 97
  • [48] A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226
    Mehta, R. S.
    Barlow, W. E.
    Albam, K. S.
    Vandenberg, T.
    Dakhil, S. R.
    Tirumali, N. R.
    Lew, D. L.
    Hayes, D. F.
    Gralow, J. R.
    Livingston, R. B.
    Hortobagyi, G. N.
    CANCER RESEARCH, 2011, 71
  • [49] Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial
    Honecker, Friedemann
    Harbeck, Nadia
    Schnabel, Claudia
    Wedding, Ulrich
    Waldenmaier, Dirk
    Saupe, Steffen
    Jaeger, Elke
    Schmidt, Marcus
    Kreienberg, Rolf
    Mueller, Lothar
    Otremba, Burkhard
    Dorn, Julia
    Warm, Mathias
    Al-Batran, Salah-Eddin
    de Wit, Maike
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (02) : 163 - 169
  • [50] A PHASE II STUDY OF S-1 AND OXALIPLATIN AS FIRST-LINE THERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC GASTRIC CANCER
    Kim, H. G.
    Kang, M.
    Kim, S.
    Lee, S. I.
    Lee, G.
    Kang, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 182 - 182
12345